focus -WSS

focus

author：comprehensive 2025-10-01 23:31:05 - browse：738

Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI, they say.

In a small study published Wednesday — just 10 people with severe, treatment-resistant depression receiving deep brain stimulation therapy — researchers used the electrodes to record brain activity and later fed the scans into a homegrown artificial intelligence system that analyzed them for patterns. They found that it was possible to track patients’ recovery through changes in brain cells’ electrical activity.

Finding so-called biomarkers, or objective measurements reflecting depression, could help diagnose depression, track its progression, predict a relapse, and better tailor therapies to individual patients. But finding those metrics has been difficult, partly because depression’s biological impact isn’t well understood.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Medicare has a new plan to address drug shortages

hotspot

WSS

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Key Senate panel to consider PBM, drug pricing reform package

STAT Virtual Event: The State of Biosimilars: What to Watch

The health care issue Democrats can’t solve: hospital reform

FDA approves RSV monoclonal antibody for infants, toddlers

Humans aren't the only ones with an imagination. Rats have it too

Wikipedia

focus

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Doctors find melanoma drugs effective against rare brain cancer

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Cancer drug shortages should be causing more outrage

At Orexo, a ‘turning point’ for everything but digital health

Moonlake's readout produced a cash windfall. Risks remain

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Affirmative action in medical school literally saved lives

Readout LOUD podcast: ESMO highlights & Roivant's big deal

knowledge

Lung cancer screening guidelines updated for cigarette smokers

Gene therapy’s promise and the high cost of hope

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Sanders adds drug shortage policies to pandemic preparedness bill

Prime Medicine says its gene editing passes test in monkeys

How to convince healthy people to buy insurance

Wikipedia

hotspot

hotspot

focus